中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2010年
12期
32-33
,共2页
金水宝胶囊%慢性肾脏病%胱抑素C%超敏C反应蛋白
金水寶膠囊%慢性腎髒病%胱抑素C%超敏C反應蛋白
금수보효낭%만성신장병%광억소C%초민C반응단백
Jinshuibao capsule%Chronic kidney disease%Cystatin C%CRP
目的 观察金水宝胶囊对慢性肾脏病(CKD)患者血清胱抑素C(Cystatin C)与超敏C反应蛋白(hs-CRP)的影响.方法 34例明确诊断CKD患者,随机分为对照组(17例)和治疗组(17例),同时选择17名健康成人作为正常对照组,在基础治疗上加用金水宝胶囊3次/d,6粒/次口服,治疗前、后8周分别检测Cystatin C、hs-CRP、Scr、BUN.结果 CKD患者Cystatin C、hs-CRP、Scr较正常对照组明显增高(P＜0.05),常规治疗8周后其Cystatin C、hs-CRP、Scr有所降低,但差异无统计学意义(P＞0.05),而加用金水宝胶囊治疗后其Cystatin C、hs-CRP、Scr明显降低(P＜0.05);Cystatin C与hs-CRP呈正相关,Cystatin C与GFR呈负相关.结论 金水宝胶囊可改善早期CKD患者的肾功能和炎症状态,有利于延缓CKD的进展.
目的 觀察金水寶膠囊對慢性腎髒病(CKD)患者血清胱抑素C(Cystatin C)與超敏C反應蛋白(hs-CRP)的影響.方法 34例明確診斷CKD患者,隨機分為對照組(17例)和治療組(17例),同時選擇17名健康成人作為正常對照組,在基礎治療上加用金水寶膠囊3次/d,6粒/次口服,治療前、後8週分彆檢測Cystatin C、hs-CRP、Scr、BUN.結果 CKD患者Cystatin C、hs-CRP、Scr較正常對照組明顯增高(P＜0.05),常規治療8週後其Cystatin C、hs-CRP、Scr有所降低,但差異無統計學意義(P＞0.05),而加用金水寶膠囊治療後其Cystatin C、hs-CRP、Scr明顯降低(P＜0.05);Cystatin C與hs-CRP呈正相關,Cystatin C與GFR呈負相關.結論 金水寶膠囊可改善早期CKD患者的腎功能和炎癥狀態,有利于延緩CKD的進展.
목적 관찰금수보효낭대만성신장병(CKD)환자혈청광억소C(Cystatin C)여초민C반응단백(hs-CRP)적영향.방법 34례명학진단CKD환자,수궤분위대조조(17례)화치료조(17례),동시선택17명건강성인작위정상대조조,재기출치료상가용금수보효낭3차/d,6립/차구복,치료전、후8주분별검측Cystatin C、hs-CRP、Scr、BUN.결과 CKD환자Cystatin C、hs-CRP、Scr교정상대조조명현증고(P＜0.05),상규치료8주후기Cystatin C、hs-CRP、Scr유소강저,단차이무통계학의의(P＞0.05),이가용금수보효낭치료후기Cystatin C、hs-CRP、Scr명현강저(P＜0.05);Cystatin C여hs-CRP정정상관,Cystatin C여GFR정부상관.결론 금수보효낭가개선조기CKD환자적신공능화염증상태,유리우연완CKD적진전.
Objective To observe the influence of jinshuibao capsule on serum cystatin C and high sensitive C-reactive (hs-CRP)protein in chronic kidney disease patients (CKD). Methods Thirty-four cases CKD patients were randomly divided into two groups: control group (17 cases) and treatment group (treatment with jinshuibao capsules, 17 cases). Meanwhile, 17 healthy adults were taken as the normal control. The blood concentrations of cystatin C, hs-CRP, Scr and BUN were determined. Results The level of cystatin C, hs-CRP,Scr in all CKD patients were significantly higher than those in the normal control(P＜ 0. 05), the level of cystatin C, hs-CRP, Scr decreased after 8 weeks of conventional treatment (P ＞ 0.05) , while those significantly decreased addition of jinshuibao capsule treatment(P ＜0. 05); Cystatin C and hs-CRP were positively correlated,but Cystatin C was negatively correlated with GFR. Conclusion The renal function and inflammation can be alleviated by jinshuibao capsule in early CKD patients, which could be slowed the progression of CKD.
